文献速递肿瘤 PET/CT

68Ga-FAPI与18F-FDG PET在多种恶性肿瘤患者中的诊断准确性比较

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
PubMed 文献 · J Nucl Med · 2024-02-08

在正在进行的68Ga-FAPI PET观察性试验中,对115例8种肿瘤患者行头对头比较,其中103例同时接受68Ga-FAPI与18F-FDG PET并有充分病灶验证用于准确性分析。68Ga-FAPI PET在结直肠癌和前列腺癌检测中准确性高于18F-FDG PET,在乳腺癌和头颈癌中两者相当,在膀胱癌、肾癌、淋巴瘤和骨髓瘤中较低。

要点

  • 68Ga-FAPI PET在结直肠癌和前列腺癌中诊断准确性高于18F-FDG PET。
  • 乳腺癌和头颈癌中两种显像剂的患者水平准确性相当。
  • 膀胱癌、肾癌、淋巴瘤和骨髓瘤中68Ga-FAPI PET准确性低于18F-FDG PET。

核心结论

  • 68Ga-FAPI PET在结直肠癌和前列腺癌诊断中准确性高于18F-FDG PET,在乳腺癌和头颈癌中诊断性能相当。
  • 准确性和对管理的影响将在正在进行的 prospective interventional 试验(NCT05160051)中进一步评估。

研究设计与样本

  • 作为正在进行的68Ga-FAPI PET观察性试验的一部分,对多种肿瘤类型进行两种显像方式的头对头比较。
  • 纳入2018年10月至2022年3月期间因肿瘤分期或再分期接受68Ga-FAPI显像的115例8种肿瘤患者。
  • 其中103例同时接受68Ga-FAPI和18F-FDG PET并有充分病灶验证用于准确性分析。
  • 每次扫描评估原发肿瘤、淋巴结、内脏和骨转移的检测。
  • 检测病灶的真假阳性与阴性基于活检或手术切除的组织病理学以及影像学验证来判定。

主要发现

  • 结直肠癌(n=14):68Ga-FAPI PET患者水平准确性85.7% vs 18F-FDG PET 78.6%,区域水平95.6% vs 91.1%。
  • 前列腺癌(n=22):68Ga-FAPI PET患者水平准确性100% vs 18F-FDG PET 90.9%,区域水平96.4% vs 92.7%。
  • 乳腺癌(n=16)患者水平准确性两者均为100%;头颈癌(n=10)两者均为90%。
  • 膀胱癌(n=12)患者水平准确性68Ga-FAPI PET 75% vs 18F-FDG PET 100%;肾癌(n=10)80% vs 90%。
  • 淋巴瘤(n=9)患者水平准确性68Ga-FAPI PET 88.9% vs 18F-FDG PET 100%;骨髓瘤(n=10)80% vs 90%。

局限性

  • 原文结论指出准确性和对管理的影响将在正在进行的 prospective interventional 试验(NCT05160051)中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess the diagnostic accuracy of 68Ga-labeled fibroblast activation protein inhibitor (FAPI) and 18F-labeled FDG PET for the detection of various tumors, we performed a head-to-head comparison of both imaging modalities across a range of tumor entities as part of our ongoing 68Ga-FAPI PET observational trial. Methods: The study included 115 patients with 8 tumor entities who received imaging with 68Ga-FAPI for tumor staging or restaging between October 2018 and March 2022. Of those, 103 patients received concomitant imaging with 68Ga-FAPI and 18F-FDG PET and had adequate lesion validation for accuracy analysis. Each scan was evaluated for the detection of primary tumor, lymph nodes, and visceral and bone metastases. True or false positivity and negativity to detected lesions was assigned on the basis of histopathology from biopsies or surgical excision, as well as imaging validation. Results: 68Ga-FAPI PET revealed higher accuracy than 18F-FDG PET in the detection of colorectal cancer (n = 14; per-patient, 85.7% vs. 78.6%; per-region, 95.6% vs. 91.1%) and prostate cancer (n = 22; per-patient, 100% vs. 90.9%; per-region, 96.4% vs. 92.7%). 68Ga-FAPI PET and 18F-FDG PET had comparable per-patient accuracy in detecting breast cancer (n = 16, 100% for both) and head and neck cancers (n = 10, 90% for both modalities). 68Ga-FAPI PET had lower per-patient accuracy than 18F-FDG PET in cancers of the bladder (n = 12, 75% vs. 100%) and kidney (n = 10, 80% vs. 90%), as well as lymphoma (n = 9, 88.9% vs. 100%) and myeloma (n = 10, 80% vs. 90%). Conclusion: 68Ga-FAPI PET demonstrated higher diagnostic accuracy than 18F-FDG PET in the diagnosis of colorectal cancer and prostate cancer, as well as comparable diagnostic performance for cancers of the breast and head and neck. Accuracy and impact on management will be further assessed in an ongoing prospective interventional trial (NCT05160051).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hirmas N, Hamacher R, Sraieb M, et al. Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies. J Nucl Med. 2024. PMID: 38331453. doi:10.2967/jnumed.123.266652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。